25doc026 10.3205/25doc026 urn:nbn:de:0183-25doc0264 Meeting Abstract Lanzl Lanzl Ines I

Chiemsee Augen Tagesklinik, Prien

author Javaheri Javaheri Michael M

Retina Specialists of Beverly Hills, Beverly Hills, USA

author Sherman Sherman Steven S

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

author Moll Moll Keran K

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

author Boucher Boucher Nick N

Vestrum Health, Naperville, IL, USA

author Singh Singh Rishi P. RP

Cleveland Clinic Martin Hospitals, Cleveland Clinic Florida, Stuart, FL, USA

author Ali Ali Ferhina S. FS

New York Medical College, Administration Building, Valhalla, NY, USA

author Borkar Borkar Durga D

Duke University Eye Center, Durham, NC, USA

author Leng Leng Theodore T

Byers Eye Institute at Stanford University, Stanford School of Medicine, Palo Alto, CA, USA

author Mehta Mehta Nitish N

NYU Langone Health, Department of Ophthalmology, New York, NY, USA

author German Medical Science GMS Publishing House

Düsseldorf

610 20250513 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0613 026 37. Internationaler Kongress der Deutschen Ophthalmochirurgie (DOC) Retina II Nürnberg 20250515 20250517 FP 3.7 TextPurpose: To describe the real-world treatment (tx) patterns among previously treated anti-VEGF-users initiating aflibercept (AFL) 8 mg for the tx of DME.Methods: Separate cohorts of previously treated eyes with DME initiating AFL 8 mg were created from electronic health records in the Intelligent Research in Sight (IRIS)® registry and Vestrum Health Retina Databases (Vestrum). Eyes initiating AFL 8 mg during 8/18/23–6/30/24 (IRIS) and 8/18/23–7/30/24 (Vestrum) were followed from initiation until last visit, tx switch or missing information on tx laterality. Mean dosing intervals were calculated during the pre-AFL 8 mg switch period (≥6 months up to 1 year), loading phase (i.e. first 3 injections or 90 days, whichever occurred first) and post-loading phase (up to end of follow-up). Dosing intervals were examined before and after switching to AFL 8mg in a subset of eyes that were consistently anti-VEGF-treated prior to switching, (defined as tx for ≥6 months and average dosing intervals of ≤8 weeks) with average dosing intervals before switching of 4–<6 or 6–≤8-weeks.Results: A total of 9.109 and 3.722 eyes initiating AFL 8 mg were included (median [Q1, Q3] months of follow-up of 3 [2, 5] and 5 [3, 8]) from IRIS and Vestrum, respectively. Patient characteristics at time of switch from IRIS and Vestrum were similar: mean age 66 years; ~56% were men, ~62% were white, and ~90% had bilateral DME. Nearly 73% switched from AFL 2 mg and 14% from faricimab. In consistently anti-VEGF-treated eyes with ≥1 post-loading phase injection (IRIS, n=1.593; Vestrum, n=427), last post-loading dosing interval was on average (mean [std]) 16 (23) and 19 (20) days longer than last observed dosing interval prior to switching, respectively. In consistently anti-VEGF-treated eyes with average pre-switch injection interval of 4–<6 weeks in IRIS (n=742) and Vestrum (n=168), dosing intervals were extended by mean (SD) of 20 (21) and 24 (20) days, respectively. In eyes with average pre-switch injection interval of 6–≤8 weeks in IRIS (n=849) and Vestrum (n=259), mean interval (SD) extension was 13 (24) and 16 (20) days, respectively.Conclusion: Early real-word experience suggests dosing intervals could be extended by 2 or more weeks among DME eyes that were consistently anti-VEGF-treated prior to initiating AFL 8 mg, with most switching from AFL 2 mg or faricimab. This abstract has been recently submitted and will be presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). 0 0 0 0